Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. (1349.HK)
HKD 2.57
(5.76%)
HKD 2.57
(5.76%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 43.65 Million CNY | 7.71% |
| 2022 | 40.52 Million CNY | 13.76% |
| 2021 | 35.62 Million CNY | -1.07% |
| 2020 | 36 Million CNY | 12.99% |
| 2019 | 31.86 Million CNY | -0.53% |
| 2018 | 32.03 Million CNY | -19.23% |
| 2017 | 39.66 Million CNY | 67.63% |
| 2016 | 23.66 Million CNY | 137.63% |
| 2015 | 9.95 Million CNY | -28.78% |
| 2014 | 13.98 Million CNY | -10.18% |
| 2013 | 15.56 Million CNY | 124.23% |
| 2012 | 6.94 Million CNY | -8.66% |
| 2011 | 7.6 Million CNY | -51.69% |
| 2010 | 15.73 Million CNY | 7.59% |
| 2009 | 14.62 Million CNY | 20.14% |
| 2008 | 12.17 Million CNY | 40.66% |
| 2007 | 8.65 Million CNY | 195.66% |
| 2006 | 2.92 Million CNY | 49.11% |
| 2005 | 1.96 Million CNY | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 46.91 Million CNY | 7.49% |
| 2024 Q2 | 52.71 Million CNY | 12.35% |
| 2023 FY | 43.65 Million CNY | 7.71% |
| 2023 Q2 | 49.54 Million CNY | -0.55% |
| 2023 Q1 | 49.82 Million CNY | 22.93% |
| 2023 Q3 | 41.12 Million CNY | -16.99% |
| 2023 Q4 | 43.65 Million CNY | 6.14% |
| 2022 Q4 | 40.52 Million CNY | 16.14% |
| 2022 FY | 40.52 Million CNY | 13.76% |
| 2022 Q3 | 34.89 Million CNY | -17.02% |
| 2022 Q2 | 42.05 Million CNY | -2.07% |
| 2022 Q1 | 42.94 Million CNY | 20.54% |
| 2021 Q3 | 40.15 Million CNY | -2.26% |
| 2021 Q2 | 41.08 Million CNY | -1.92% |
| 2021 FY | 35.62 Million CNY | -1.07% |
| 2021 Q1 | 41.88 Million CNY | 16.32% |
| 2021 Q4 | 35.62 Million CNY | -11.28% |
| 2020 Q1 | 39.84 Million CNY | 25.02% |
| 2020 Q2 | 41.2 Million CNY | 3.43% |
| 2020 Q3 | 38.75 Million CNY | -5.96% |
| 2020 Q4 | 36 Million CNY | -7.08% |
| 2020 FY | 36 Million CNY | 12.99% |
| 2019 Q1 | - CNY | -100.0% |
| 2019 Q2 | 36.95 Million CNY | 0.0% |
| 2019 Q4 | 31.86 Million CNY | 0.0% |
| 2019 FY | 31.86 Million CNY | -0.53% |
| 2018 Q1 | 36.85 Million CNY | -7.08% |
| 2018 Q4 | 32.03 Million CNY | -0.0% |
| 2018 Q3 | 32.03 Million CNY | -13.08% |
| 2018 FY | 32.03 Million CNY | -19.23% |
| 2018 Q2 | 36.85 Million CNY | 0.0% |
| 2017 FY | 39.66 Million CNY | 67.63% |
| 2017 Q3 | 39.66 Million CNY | 12.6% |
| 2017 Q2 | 35.22 Million CNY | 0.0% |
| 2017 Q1 | 35.22 Million CNY | 48.88% |
| 2017 Q4 | 39.66 Million CNY | 0.0% |
| 2016 Q2 | 19.07 Million CNY | 0.0% |
| 2016 Q4 | 23.66 Million CNY | 0.0% |
| 2016 FY | 23.66 Million CNY | 137.63% |
| 2016 Q1 | 19.07 Million CNY | 91.55% |
| 2016 Q3 | 23.66 Million CNY | 24.05% |
| 2015 Q3 | 9.95 Million CNY | -49.89% |
| 2015 FY | 9.95 Million CNY | -28.78% |
| 2015 Q2 | 19.87 Million CNY | 0.0% |
| 2015 Q4 | 9.95 Million CNY | 0.0% |
| 2015 Q1 | 19.87 Million CNY | 42.11% |
| 2014 FY | 13.98 Million CNY | -10.18% |
| 2014 Q4 | 13.98 Million CNY | 0.0% |
| 2014 Q3 | 13.98 Million CNY | -42.57% |
| 2014 Q2 | 24.34 Million CNY | 0.0% |
| 2014 Q1 | 24.34 Million CNY | 56.39% |
| 2013 Q2 | 15.07 Million CNY | 0.0% |
| 2013 Q4 | 15.56 Million CNY | 0.0% |
| 2013 FY | 15.56 Million CNY | 124.23% |
| 2013 Q1 | - CNY | -100.0% |
| 2012 Q2 | 20.95 Million CNY | 0.0% |
| 2012 FY | 6.94 Million CNY | -8.66% |
| 2012 Q4 | 6.94 Million CNY | 0.0% |
| 2011 FY | 7.6 Million CNY | -51.69% |
| 2011 Q2 | 17.74 Million CNY | 0.0% |
| 2011 Q4 | 18.72 Million CNY | 0.0% |
| 2010 Q2 | 19.65 Million CNY | 0.0% |
| 2010 FY | 15.73 Million CNY | 7.59% |
| 2010 Q4 | 15.73 Million CNY | 0.0% |
| 2009 FY | 14.62 Million CNY | 20.14% |
| 2008 FY | 12.17 Million CNY | 40.66% |
| 2007 FY | 8.65 Million CNY | 195.66% |
| 2006 FY | 2.92 Million CNY | 49.11% |
| 2005 FY | 1.96 Million CNY | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 12.19 Million HKD | -257.886% |
| Grand Pharmaceutical Group Limited | 1.38 Billion HKD | 96.857% |
| Extrawell Pharmaceutical Holdings Limited | 7.26 Million HKD | -500.845% |
| Wai Yuen Tong Medicine Holdings Limited | 308.09 Million HKD | 85.832% |
| Qianhai Health Holdings Limited | 431.78 Million HKD | 89.891% |
| Lee's Pharmaceutical Holdings Limited | 298.1 Million HKD | 85.357% |
| Essex Bio-Technology Limited | 62.82 Million HKD | 30.516% |
| Tongfang Kontafarma Holdings Limited | 98.26 Million HKD | 55.578% |
| PuraPharm Corporation Limited | 175.59 Million HKD | 75.141% |
| SSY Group Limited | 1.08 Billion HKD | 95.982% |
| JBM (Healthcare) Limited | 91.58 Million HKD | 52.338% |
| Jacobson Pharma Corporation Limited | 317.85 Million HKD | 86.267% |
| China Resources Pharmaceutical Group Limited | 35.09 Billion HKD | 99.876% |